<DOC>
	<DOCNO>NCT01983241</DOCNO>
	<brief_summary>This multi-center , randomize , placebo-controlled , double blind clinical study ass efficacy safety two separate dose regimen Alpha-1 MP versus placebo 156 week ( i.e. , 3 year ) use compute tomography ( CT ) lungs main measure efficacy . The two Alpha-1 MP dos test 60 mg/kg 120 mg/kg administer weekly IV infusion 156 week . The study consist Screening Phase , 156-week Treatment Phase , End Study Visit Week 160 .</brief_summary>
	<brief_title>Efficacy Safety Alpha1-Proteinase Inhibitor ( Human ) , Modified Process ( Alpha-1 MP ) Subjects With Pulmonary Emphysema Due Alpha1 Antitrypsin Deficiency ( AATD )</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Have document total alpha1PI serum level &lt; 11 µM . Have diagnosis congenital AATD allelic combination ZZ , SZ , Z ( null ) , ( null ) ( null ) , S ( null ) , `` atrisk '' allele . At Screening ( Week 3 ) Visit , postbronchodilator force expiratory volume 1 second ( FEV1 ) ≥ 30 % &lt; 80 % predict FEV1/forced vital capacity ( FVC ) &lt; 70 % ( Global Initiative Chronic Obstructive Lung Disease [ GOLD ] stage II III ) . Have carbon monoxide diffuse capacity ( DLCO ) ≤ 60 % predict ( correct HgB ) within past 2 year OR evidence pulmonary emphysema CT scan within past 2 year per Investigator 's judgment . Have clinical evidence pulmonary emphysema per Investigator 's judgment . Has receive alpha1PI augmentation therapy 1 month within six month prior Screening Visit . Has receive alpha1PI augmentation therapy within one month Screening Visit . Has chronic obstructive pulmonary disease ( COPD ) exacerbation within 5 week prior Screening Visit Screening Phase . Unable physically ( e.g. , unable fit inside CT scanner ) mentally ( e.g. , claustrophobic ) undergo CT scan . History lung liver transplant . Any lung surgery past 2 year ( exclude lung biopsy ) . On wait list lung surgery , include lung transplant . Smoking past 12 month positive urine cotinine test screening due smoking . Maybe Nicotine replacement , include vapor cigarette . History anaphylaxis severe systemic response plasmaderived alpha1PI preparation blood product ( ) . Use systemic steroid stable dose equivalent 5 mg/day prednisone ( i.e. , 10 mg every 2 day ) within 5 week prior Screening Visit ( inhaled steroid consider systemic steroid ) Screening Phase . Use systemic aerosolize antibiotic COPD exacerbation within 5 week prior Screening Visit Screening Phase . Known selective severe Immunoglobulin A ( IgA ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pulmonary Emphysema</keyword>
	<keyword>Alpha-1 Antitrypsin Deficiency</keyword>
	<keyword>AATD</keyword>
	<keyword>Alpha-1 PI Deficiency</keyword>
	<keyword>Alpha-1 Protienase Inhibitor</keyword>
</DOC>